Singapore Clinical Trial: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy ... Read More

Clinical Trial: Artificial Intelligence-Assisted Advanced Analysis of Knee Imaging and Outcome Prediction

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07721116) titled 'Artificial Intelligence-Assisted Advanced Analysis of Knee Imaging and Outcome Prediction' ... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy ... Read More

Clinical Trial: COMPARING EFFECTS OF NINTENDO EXERGAMING TO A NO INTERVENTION CONTROL GROUP

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07720427) titled 'COMPARING EFFECTS OF NINTENDO EXERGAMING TO A NO INTERVENTION CONTROL GROUP' on July 17. B... Read More

Singapore Clinical Trial: A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient’s current antipsychotic medication(s).

Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, m... Read More

Clinical Trial: Efficacy of Adding Intrathecal Morphine to Erector Spinae Plane Block for Postoperative Analgesia After Midline Laparotomy

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07720739) titled 'Efficacy of Adding Intrathecal Morphine to Erector Spinae Plane Block for Postoperative Ana... Read More

Singapore Clinical Trial: A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3537031 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3537031 in Healthy Participants

Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability ... Read More

Singapore Clinical Trial: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab... Read More

Clinical Trial: Exploratory Study of Peristomal and Non-Peristomal Skin Barrier Characteristics in People With a Stoma

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07719309) titled 'Exploratory Study of Peristomal and Non-Peristomal Skin Barrier Characteristics in People W... Read More

Singapore Clinical Trial: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator’s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety o... Read More

• ««
• «
• 170361
• 170362
• 170363
• 170364
• 170365
• 170366
• 170367
• 170368
• 170369
• 170370
• »
• »»